(Q37877743)

24 August 2017

1 reference

title

Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia (English)

1 reference

Maryalice Stetler-Stevenson

24 August 2017

1 reference

3

object named as

Maryalice Stetler-Stevenson

1 reference

24 August 2017

5

Wyndham H Wilson

1 reference

24 August 2017

Robert J Kreitman

1

1 reference

24 August 2017

Evgeny Arons

2

1 reference

24 August 2017

David J P Fitzgerald

4

1 reference

24 August 2017

Ira Pastan

6

1 reference

24 August 2017

publication date

1 June 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

52 Suppl 2

1 reference

24 August 2017

page(s)

82-86

1 reference

Extended follow-up of patients with hairy cell leukemia after treatment with cladribine

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.565843

Pentostatin: impact on outcome in hairy cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.565843

Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.565843

Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.565843

Immunotoxin treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.565843

Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.565843

Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.565843

Eradication of minimal residual disease in hairy cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.565843

Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.565843

Responses in refractory hairy cell leukemia to a recombinant immunotoxin

21 January 2018

1 reference

12 December 2020

Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies

1 reference

12 December 2020

Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies

1 reference

12 December 2020

Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.

1 reference

12 December 2020

10.3109/10428194.2011.565843

Identifiers

DOI

1 reference

24 August 2017

1 reference